NEW DELHI, Apr 6: Drug firm Lupin today said it has received an Establishment Inspection Report (EIR) from the US health regulator for its Pithampur, Unit 1 manufacturing facility in Madhya Pradesh.
The inspection was conducted in July 2017, it said in a BSE filing.
USFDA gives EIR on closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.
In November last, Lupin had received warning letter from USFDA (US Food and Drug Administration) for its manufacturing facilities in Goa and Pithampur.
(PTI)
Trending Now
E-Paper
Follow our WhatsApp channel